The utilization of opioids, compounds, and physician-dispensed medications have significantly decreased.
The utilization of opioids, compounds, and physician-dispensed medications have significantly decreased.
Proposed changes to who can grow and research marijuana will soon be available for public commentary.
An Oklahoma judge found the drug maker to be partially responsible for the harm of the opioid epidemic.
Healthesystems’ Chief Medical Officer explores trends impacting workers’ comp, including patient engagement, population health, and more.
Nine generic versions of Lyrica (pregabalin) have been approved for the treatment of five different medical conditions.
Sandy Shtab has been recognized for making significant contributions to the workers’ comp industry.
Looking at over 29 billion private health claims, this study found that claim lines related to telehealth rose 624% from 2014-2018.
While many states report fewer opioid prescriptions, MME levels vary more significantly by state.
NCCI estimates that a 25-75% reduction in motor vehicle accidents in workers’ comp could save $1-4 billion, creating interest in self-driving cars.
Generic versions of Ultram (tramadol hydrochloride) tablets and Dyloject (diclofenac sodium) injections have been approved by the FDA.
While the utilization of opioids and other problematic drugs decreased, similar drops were seen in states without closed formularies.
Stephanie Arkelian has been recognized as a talented young professional making a positive impact on the workers’ comp industry.
Beyond exceptions for safety or federal positions, employers cannot refuse employment for testing positive for marijuana in pre-employment drug screenings.
A new study builds upon earlier research with a larger, more up-to-date dataset, finding a reversal in trends.
Visit Healthesystems in booth #909 and learn how we’re making waves in workers’ comp, and how we hope to benefit coastal cleanups for the “Coast to Coast” theme.
Orphengesic Forte has received a decision date of August 14, 2019.
How services like Lyft and Uber can amplify injured worker transportation programs to improve claims outcomes.
Though they’re only needed for special cases in workers’ comp, anticancer medications can easily exceed $10,000 per monthly fill.
In a call for public comment, the FDA believes that reducing excess opioid supplies can lower opioid misuse, abuse, and overdose.
The life saving antidote for opioid overdose will soon be available in a consumer-friendly, generic nasal spray.
Healthesystems partnered with Risk & Insurance magazine to survey 500+ work comp professionals on their top challenges, trends, successes, and more.
Combining all three drugs can reduce claim closure rates to 58.3%, with average claim costs of $94,000.
Florida enacted a law to cover 21 different cancers, while other states like Montana, Maryland, and Virginia have recently passed similar laws.
Four research sites will test proven opioid prevention and treatment interventions, hoping to reduce overdose deaths by 40% over three years.
New changes to REMS safety programs will require stronger treatment documentation and oversight.
Patient engagement can lead to better health outcomes, but not all engagement strategies are equally effective.
The workforce is aging, getting younger, and gaining more women, all at once. What does that mean for claims management?
Congress may soon clear federal restrictions to processing marijuana transactions, while the FDA asks for feedback on handling marijuana products.
Various state and local governments have sued drug developers for the harms of the opioid epidemic, and this could be the first of many settlements.
Phase 3 clinical trials for this non-opioid drug demonstrate significant reductions in pain for osteoarthritis and chronic low-back pain.
Demographic factors such as gender, ethnicity, socioeconomic status, age, and location can impact opioid risks.
Despite having little clinical impact, topical creams continue to be utilized widely in workers’ comp.
Federal lawmakers and administrative agencies continue to investigate how to best lower ever-increasing drug prices.
Can special implants in the brain override paralysis? The FDA believes one day they could.
The FDA created special drug labels to clear a development hurdle and encourage manufacturers.
Dr. Robert Goldberg and Sandy Shtab talk with Risk & Insurance about changing attitudes and policies around medical marijuana, its potential role in reducing reliance on opioids, and what this can mean for payers, employers, patients and PBMs.
Prescribing has doubled since 2003, overdose deaths quadrupled since 1996, and misuse accounts for 20% of benzodiazepine use.
Kentucky, Connecticut, Idaho, and West Virginia proposed bills to make PTSD compensable for first responders.
The opioid prodrug for acute pain will soon be available in both a stronger and weaker dose.
As 2018’s legislative trends continue to spill into 2019, what big initiatives might impact workers’ comp this year?
An analysis of 90,000 private claims explores the relationship between early PT and reduced long-term opioid use in musculoskeletal pain.
Can doctors in certain states refer patients to pharmacies which they partially own?
Will doctors one day prescribe apps meant to drive behavior changes instead of drugs?
The reSET-O app uses cognitive behavioral therapy techniques to assist patients engaged in medication-assisted therapy for opioid dependence.
Formulary and claims management considerations for populations at risk for “mental-only” cases of PTSD.
The American Gastroenterological Association released guidance on properly prescribing medications for OIC.
Marijuana use among adults aged 50-64 tripled from 2002-2014.
Dr. Silvia Sacalis of Healthesystems teamed up with Dr. Adam Seidner of The Hartford for a session at NWCDC – here are 5 key takeaways.
Five-to-ten times stronger than fentanyl, this drug is not for consumer use, and many claim it could worsen the opioid crisis.
Healthesystems’ clinical leaders comment on the collective responsibility of healthcare entities, providers, and legislators to increase efforts that will help stem opioid overprescribing, misuse and overdose.
More states allow for the legalization of recreational and medical marijuana, while others consider insurance reimbursement.
A study of 9,596 claimants who filled an opioid prescription found that 30% were still taking opioids 90 days later.
Join our VP of Clinical Services on December 6th in Las Vegas for a presentation on value-based care in workers’ comp.
The marijuana-derived seizure drug now sits at schedule V, facing far fewer prescribing and dispensing restrictions.
Healthesystems’ VP of Clinical Services offers insight into prescriptions in workers’ comp claims that should raise concerns.
Assembly No. 4505 may solidify precedence recently made by a judge from the Division of Workers’ Compensation.
Common risk factors can increase worker fatigue, leading to more frequent workplace injuries and a loss of productivity.
With an enormous range of initiatives to prevent and treat opioid use disorder, the bill has officially been signed by the President.
Cassipa (buprenorphine and naloxone) sublingual film delivers a new dosage for the treatment of opioid dependence.
Healthesystems’ VP of Clinical Services explains how too many drugs in a claim can cause health concerns, and what can be done to prevent them.
